Five leading scientists were ousted from the annual meeting of the American Diabetes Association (ADA) in New Orleans on Friday. Their crime: handing out copies of an editorial, published in the ...

By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Multiple Presentations for DA-1726 and Vanoglipel at ADA 2026 On June 8, 2026, MetaVia, Inc. (NASDAQ: MTVA) ...

Late-breaking data for retatrutide, CagriSema, survodutide, and oral elecoglipron are poised to reshape near-term formulary strategy and utilization management for obesity and metabolic disease.

There were extraordinary scenes at the Scientific Sessions of the American Diabetes Association (ADA) in New Orleans earlier ...

On the morning of June 5, 2026, attendees queued outside the main hall of the Ernest N. Morial Convention Center in New Orleans for the American Diabetes Association (ADA) Scientific Sessions. The ...

Daewon Pharmaceutical will present key preclinical data on a next-generation quadruple-action obesity drug candidate at one ...

Wider use of continuous glucose monitoring (CGM), glycemic management during cancer treatment, and individualized dosing of obesity drugs in people with diabetes are just a few of the new topics and ...

Key obesity data from Eli Lilly, Boehringer Ingelheim and Sciwind Biosciences captivated ADA 2026 attendees.

Experts at ADA 2026 say nutrition guidelines must be personalized, culturally responsive, and built on research that reflects the patients they're meant to serve. In a VESALIUS-CV subgroup analysis, ...

THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1 diabetes ...

Amid intense backlash, the head of the American Diabetes Association posted a video Wednesday apologizing for the organization’s decision on Friday to forcefully remove five leading diabetes ...

At the event, Novo Nordisk also announced that U.S. prescriptions for the pill-based version of Wegovy just hit 3 million.